Bacterial Vaginosis

8
Pipeline Programs
5
Companies
6
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
1
1
0
2
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
5100%
+ 3 programs with unclassified modality

On Market (1)

Approved therapies currently available

Mission Therapeutics
TINDAMAXApproved
tinidazole
Mission Therapeutics
oral2004

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Mission Therapeutics
Mission TherapeuticsUK - Cambridge
2 programs
1
1
1
TinidazolePhase 3Small Molecule1 trial
tinidazolePhase 1Small Molecule1 trial
Active Trials
NCT00510614Completed37Est. Sep 2009
NCT00229216Completed200Est. Jun 2007
Mission Pharmacal
Mission PharmacalTX - San Antonio
2 programs
1
1
TinidazolePhase 3Small Molecule
tinidazolePhase 1Small Molecule
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
1
1
Neo-Penotran® FortePhase 21 trial
750 mg metronidazole/ 200 mg miconazole vaginal suppositoryPhase 11 trial
Active Trials
NCT02185456UnknownEst. Mar 2016
NCT01230814CompletedEst. Aug 2013
Teva
TevaIsrael - Petach Tikva
1 program
1
MetronidazolePhase 1/2Small Molecule1 trial
Active Trials
NCT01020396Completed579Est. Mar 2003
Roche
RocheSTAVANGER NORWAY, Norway
1 program
cobas® BV/CV testN/A1 trial
Active Trials
NCT06975436Completed738Est. Jun 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Mission TherapeuticsTinidazole
Allergy TherapeuticsNeo-Penotran® Forte
TevaMetronidazole
Allergy Therapeutics750 mg metronidazole/ 200 mg miconazole vaginal suppository
Mission Therapeuticstinidazole
Rochecobas® BV/CV test

Clinical Trials (6)

Total enrollment: 1,554 patients across 6 trials

NCT00229216Mission TherapeuticsTinidazole

Treatment of Bacterial Vaginosis With Oral Tinidazole

Start: Jan 2005Est. completion: Jun 2007200 patients
Phase 3Completed
NCT01230814Allergy TherapeuticsNeo-Penotran® Forte

Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women

Start: Apr 2011Est. completion: Aug 2013
Phase 2Completed
NCT01020396TevaMetronidazole

Bioequivalence of Metronidazole Gel, 0.75% in the Treatment of Bacterial Vaginosis

Start: Jan 2002Est. completion: Mar 2003579 patients
Phase 1/2Completed
NCT02185456Allergy Therapeutics750 mg metronidazole/ 200 mg miconazole vaginal suppository

Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis

Start: Sep 2014Est. completion: Mar 2016
Phase 1Unknown
NCT00510614Mission Therapeuticstinidazole

Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study

Start: Oct 2007Est. completion: Sep 200937 patients
Phase 1Completed
NCT06975436Rochecobas® BV/CV test

Performance Study of the Cobas® BV/CV Test on Samples From Participants With and Without Symptoms of Bacterial Vaginosis and Candida Vaginitis

Start: Dec 2024Est. completion: Jun 2025738 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
Small Molecule is the dominant modality (100% of programs)
5 companies competing in this space